Press
Press Releases
NOVEMBER 28, 2022
Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines
Hugel Aesthetics announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults.
October 25, 2022
Hugel Aesthetics Receives FDA Acceptance of BLA Resubmission for LetibotulinumtoxinA for Injection for Glabellar Lines
Hugel Aesthetics announced the acceptance of its Biologics License Application for letibotulinumtoxinA, by the U.S. Food and Drug Administration (“FDA”).
OCTOBER 6, 2022
Hugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for Glabellar Lines to the FDA
Hugel Aesthetics announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
OCTOBER 5, 2022
Hugel Aesthetics to Present Data from Phase 3 Clinical Trial At 2022 American Society of Dermatologic Surgery Annual Meeting
Hugel Aesthetics announced a presentation at the ASDS annual meeting highlighting data from its phase 3 clinical trial, BLESS III, assessing the efficacy of letibotulinumtoxinA in improving the psychosocial health-related QoL of subjects with moderate to severe glabellar lines.
JULY 27, 2022
New Published Data Supports the Safety and Efficacy of LetibotulinumtoxinA for the Treatment of Glabellar Lines
Hugel Aesthetics announces the publication of the BLESS III clinical trial in the Aesthetic Surgery Journal. The published data comes as Hugel is accelerating its efforts towards becoming a leading global medical aesthetics company.
JUNE 23, 2022
Croma Aesthetics Canada Ltd. Receives Canadian Market Authorization for Letybo (LetibotulinumtoxinA for Injection) for the Treatment of Glabellar Lines
Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.
MAY 24, 2022
Global Aesthetics Brand Hugel Inc. Accelerates the Leap Forward as a Global Company Appointing ‘Brent Saunders’, a World-Class Expert in the Medical Aesthetic Industry
Hugel Inc. announced to convene an extraordinary general shareholders’ meeting to appoint Brent Saunders to the Board as a non-executive director.
JANUARY 27, 2022
Hugel America, Inc. Announces Successful Completion of Croma-Pharma’s Decentralized Procedure for Letybo® (LetibotulinumtoxinA for Injection) in Europe
Hugel America, Inc., a growth-focused joint venture between aesthetic market-leading partners Hugel Inc., and Croma-Pharma GmbH (Croma), announced that Croma has completed the decentralized procedure in Europe for Letybo® (LetibotulinumtoxinA for Injection) to treat glabellar (frown) lines.